
In The Name Of God



ANEMIA




Present By: Mohadeseh Aghasi

<u> 1917 - Bullius Garillus (2001)</u>

Insta: Draghasi.diet





Female
Weakness
Pica
Hair loss



CBC

HEMATO / (CBC) - BLOOD

| Test | esult | Reference Intervals | Unit | WBC D | IFFERENTIAL | RBC MORPHOLOGY |
|--------|-------|---------------------|-----------|-------------------|----------------|--------------------------------|
| WBC | 8.8 | 4.5-11.0 | x 1000 | Neutrophil | 50 | Unremarkable morphology of RBC |
| RBC | 4.57 | 4.0-5.2 | x 1000000 | Lymphocyte | 40 | |
| HGB | 14.0 | 12-16 (| g/dl | Monocyte Eos | 8 | - |
| HCT | 41.8 | 36-46 | % | Band | **a | • |
| MCV | 91.5 | 80-100 | fl | Baso | 1 | 1 |
| MCH | 30.6 | 26-34 | Pg | Meta Myelocyte | | |
| MCHC | 33.5 | 31-37 | % | Pro-Myelocyte | (- | |
| PLT | 269 | 140-400 | x 1000 | Blasts | 33 | |
| RDW-SD | 40.9 | 36.4 - 46.3 | fl | Others | 124 | |
| RDW-CV | 12.2 | 11.6 - 14.4 | % | Nrbc/100 wbc | * | |
| PDW | 17.7 | 9.9 - 15.4 | fl | | | |
| MPV | 12.7 | 9.4 - 12.4 | fl | | | |

Checked By: F. Estají

Released By: N. Haj Sadeghi, M D



No.558, West Taleghani St. Tehran, Iran Tel: 62974 www.danesh-lab.com

خيابات طالفاني غربي، بين وصال و فريمان، بلاک 558

تلفن: 62974-021

diagnose diagnose diagnose diagnose diagnose diagnose se a 9 diagnose

Hb

World Health Organization women are hemoglobin <1;

Normal hematologic parameters in adults

| Parameter | Men | Women | | |
|---|--------------|--------------|--|--|
| Hemoglobin (g/dL) | 13.6 to 16.9 | 11.9 to 14.8 | | |
| Hematocrit (%) | 40 to 50 | 35 to 43 | | |
| RBC count (× 10 ⁶ /microL) | 4.2 to 5.7 | 3.8 to 5.0 | | |
| MCV (fL) | 82.5 to 98 | | | |
| MCHC | 32.5 to 35.2 | | | |
| RDW (%) | 11.4 to 13.5 | | | |
| Reticulocyte count (x 10 ³ /microL or x 10 ⁹ /L) | 16 to 130 | 16 to 98 | | |
| Platelet count (× 10 ³ /microL) | 152 to 324 | 153 to 361 | | |
| WBC count (× 10 ³ /microL) | 3.8 to 10.4 | | | |

These parameters were determined for approximately 1500 to 2000 individuals ages 20 to 80 (varies slightly by category). Reference ranges may differ depending on the instrument used. Refer to the laboratory-specific reference values provided with the individual's results.

CBC: complete blood count; RBC: red blood cell; MCV: mean corpuscular volume; fL: femtoliter; MCHC: mean corpuscular hemoglobin concentration; RDW: red cell distribution width; WBC: white blood cell.

Data from:

- Adeli K, Raizman JE, Chen Y, et al. Complex Biological Profile of Hematologic Markers across Pediatric, Adult, and Geriatric Ages: Establishment of Robust Pediatric and Adult Reference Intervals on the Basis of the Canadian Health Measures Survey. Clinical Chemistry 2015; 61:1075.
- Van den Bossche J, Devreese K, Malfait R, et al. Reference Intervals for a Complete Blood Count Determined on Different Automated Haematology Analysers: Abx Pentra 120 Retic, Coulter Gen-S, Sysmex SE 9500, Abbott Cell Dyn 4000 and Bayer Advia 120. Clin Chem Lab Med 2002; 40:69.



Causes of lower values

- hemoglobin remains ≥11 g/dL in the first trimester,
- ≥10.5 g/dL in the second trimester,
- and ≥10.5 g/dL in the third trimester

Causes of higher values (may occasionally mask underlying anemia)

levels

inere

diarrhea

Individu

hemoconcentration.

Case:

Male, wt: 70 kg, Hb: 17, HCT: 50%,

Intake:1000cc

Diagnosis & treatment?

ivery.

omiting or I HCT due to


Case:

Male, wt: 70 kg, Hb: 17, HCT: 50%, Intake:1000cc

Diagnosis & treatment?

MCV/MCH/MCHC


 Mean corpuscular the RBCs




 MCH(30±3): Mean corpuscular hemoglobin (MCH) is the average hemoglobin content in a RBC

 MCHC (33±2%) Mean corpuscular hemoglobin concentration (MCHC) is the average hemoglobin concentration per RBC

Anemia evaluation in outpatients (nonpregnant adults)



RDW: 11.5-14.5



- the degree of anisocytosis on the peripheral blood smear
- A high RDW implies a large variation in RBC sizes (IDA)
- and a low RDW implies a more homogeneous population of RBCs (Thalasemia)
- high RDW can be seen in a number of anemias,
- including iron deficiency, vitamin B12 or folate deficiency, myelodysplastic syndrome (MDS), and hemoglobinopathies, as well as in patients with anemia who have received transfusions

Very Iow MCV

 Iron deficiency and thalassemia are the most likely causes of a very low MCV (<80 fL).

Case:

Hb:7 MCV: 65 MCH: 21

• RDW: 12% ?

• DRW: 28%?

Case:

Female, Hb: 11.5, MCV: 75, MCH: 25

Diagnosis & treatment?

IDA or Thalasemia

- Mentzer index is useful in predicting the likelihood of thalassemia trait versus iron deficiency.
- If the ratio of MCV / RBC is less than 13, thalassemia is more likely than iron deficiency

IDA or Thalasemia?

Golestan Medical Laboratory No. 327. Corner of 1 Goldin St. Barkson For 34. 22550550 - 22545334 Fax: 22590659 Fmail: golestanmedlab@vahgo.com.



آزمایشگاه گلستان

43.3% 6.1% 2.1% 0.4%

شمساره بذيرش: ٢٠٩٧-٢-١١ اشتراك: ٢٢٩٧-٣۶٤٨١ تاريخ بذيرش: ١٣٩٢/١١١/٢٣ يزشك معالج: آقاى دكتو رضواني


نام مراجعه كتنده: خانم وحيده حسن زاده سن: ۳۰ سال

| Hematology Test CBC | | Result | <u>Unit</u> | Expected Value | Differential Neutrophils Lymphocytes | 48.1 % 43.3 % |
|---------------------|---|--------|-------------|-----------------------|--------------------------------------|------------------|
| CBC WBCs | | 6510 | /uL | 4000-11000 | Monocytes | 6.1 % |
| RBCs | Н | 5.75 | mil/uL | 4.2-5.4 | Eosinophils | 2.1 9 |
| Hb | | 12.0 | g/dL | 12-16 37-47 | Basophils | 0.4 |
| Hct | | 39.2 | % | 77-97 | | |
| MCV | L | 68.2 | fL | 26-34 | | |
| MCH | L | 20.9 | pg a/dl | 32-36 | | |
| MCHC | L | | g/dL /uL | 150000-400000 | | |
| Platelets | | 276000 | /UL % | 11-14 | | |
| | | 13.3 | 70 fL | 9.3-18 | | |
| RDW-CV | | 16.5 | | 7.5-11.0 | | |
| PDW | Н | 11.8 | fL | 20-36 | | |
| MPV | Н | 54.7 | % | | | |
| P-LCR | | (++) | | | | |
| Hypochromia | | (++) | | | | |
| Microcytosis | | (2.7) | | r Hamatology Analyzer | MINDRAY BC-5800 | ١. |

CBC results reported by Fully Automated 5 part diff Hematology Analyzer MINDRAY

Thecked by : Saadat

CAUSES AND RISK FACTORS FOR IRON **DEFICIENCY**



- Overt bleeding is obvious and not difficult for the clinician to recognize, often by history alone:
- Traumatic hemorrhage
- Heavy menstrual bleeding
- Hematuria

- Hemoptysis
- Pregnancy and delivery

 Typical iron loss during pregnancy has been estimated at approximately 1000 mg for pregnancy, delivery, and nursing. Menstrual blood losses account for approximately 1 mg of iron loss per day

```
بیشترین میران المیراز اید آهن:
شیرخواری
بارداری: ۳ماهه دوم و سوم
مارداری
```

IDA in pregnancy

- should have prompt testing for iron deficiency because it is the most common cause of nonphysiologic anemia in pregnancy.
- Microcytosis may be present, but microcytosis is a late finding of iron deficiency and may also be caused by thalassemia.
- Thus, the absence of microcytosis does not eliminate the possibility of iron deficiency and the presence of microcytosis does not confirm it

- For most women, iron deficiency can be assessed with a
- ferritin level
- (TSAT) or other testing.

ferritin level <30 ng/mL (<30 mcg/L) or a TSAT <20 percent is sufficient for diagnosis of iron deficiency,

and a ferritin level ≥30 ng/mL is sufficient to exclude iron deficiency if there are no comorbidities

Prevention of iron deficiency

- supplemental oral iron to all pregnant women to compensate for the increased iron demands during pregnancy and delivery
- CDC: recommends that all pregnant women begin a 30 mg/day iron supplement at the first prenatal visit
- approximately to the amount of iron in most iron-containing prenatal vitamins
- women who are intolerant of the iron in prenatal vitamins,
 it may be possible to take prenatal vitamins without iron and to supplement with oral iron supplements on an every-other-day basis (typical dose, 60 mg once every other day)





Oral iron products

Drug Ferrous fumarate (Contains 33% elemental iron per mg of mineral salt)



Elemental iron content (mg iron per mg tablet or per mL liquid)*

29.5 mg/90 mg

150 mg elemental iror

106 mg/324 or 325 mg

24

Ferrous gluconate

(Contains approximately 10 to 14% elemental iron per mg of mineral salt)

Tablets

Fergon, Ferrotabs

Ferretts, Ferrocite,

Hemocyte

Various over-the-counter and store-brand products with "iron" in the name 27 mg/240 mg


28 mg/256 mg or 38 n 325 mg



| | Ferrous sulfate (Generally contain 20 to 30%) | ■ Liquids | Multiple concentrations exist; check packaging closely | |
|-----------|---|---|---|--|
| elemental | elemental iron per mg of mineral salt but can vary by | الرس وكثره و | 15 mg/1 mL ("drops," "solution") | |
| | manuracturer) | مردس سوهات | 44 mg/5 mL ("elixir," "liquid") | |
| | | FERROUS SULFATE | 60 mg/5 mL ("syrup") | |
| | | ■ Tablets | | |
| | | Feosol original | 65 mg/200 mg | |
| | | Ferro-Bob, FerrouSul | 65 mg/325 mg | |
| | Polysaccharide-iron complex | ■ Liquids | | |
| | (PIC) (Also available as PIC plus folic | NovaFerrum | 15 mg/1 mL ("drops") | |
| | acid and PIC plus folic acid and | NovaFerrum 125 | 125 mg/5 mL ("liquid") | |
| vitamin B | vitamin B12) | Capsules | | |
| | | EZFE 200, Ferrex 150, Ferric-X 150, iFerex 150, Myferon 150, NovaFerrum 50, Nu-Iron 150, PIC 200, Poly-Iron 150 | The number in the name is the mg of elemental iron (eg, NovaFerrum 50 contains 50 mg elemental iron per capsule) | |

Prevention of iron deficiency

 Prenatal vitamins with iron are used to prevent iron deficiency that may occur due to the increased iron demands of pregnancy









Treatment of iron deficiency

First trimester — In the first trimester, we use oral iron (typical dose, one tablet containing 60 mg of elemental iron every other day or on Monday, Wednesday, and Friday

Second and third trimesters – For certain women, intravenous iron may be appropriate or preferred

cannot absorb oral iron

those who do not have the expected increase in hemoglobin level with oral ir


those with severe iron deficiency anemia (eg, hemoglobin level of 8 to 10 g/dL

those started on iron in the third trimester (after week 30, when there may be insufficient time to replete iron stores with oral iron





Algorithm for evaluating and treating iron deficiency in pregnancy



Diet

- blood loss
- dietary intake
 - reduced absorption
- Dietary heme iron (iron from better absorbed than non-he

Factors influencing the absorption and bioavailability of dietary iron

Absorption of heme iron Amount of heme iron, especially in meat Content of calcium in the meal (calcium impairs iron absorption) Absorption of nonheme iron Iron status Amount of potentially available nonheme iron Balance between positive and negative factors Positive factors Meat or fish (factors in meat other than heme iron enhance absorption of nonheme iron) Negative factors Phytate (in bran, oats, rye fiber) Polyphenols (in tea, some vegetables and cereals) Dietary calcium Soy protein

Nutritional Considerations

a balanced vegetarian diet that includes legumes, fortified or whole grains, dried fruit, nuts, seeds, and green vegetables easily provides adequate iron

Dairy products and eggs are very poor sources of iron and decrease iron absorption

- Caseins from milk and calcium inhibit iron absorption
- Iron status measured as serum ferritin is inversely associated with greater consumption of dairy products in toddlers
- consume dairy products (milk, cheese and other foods made from milk)
 as a between meal snack
- Eggs (especially yolks) also appear to inhibit iron absorption (phosvitin)

Nutritional Considerations

Fruits and vegetables aid the absorption of nonheme iron.

Fruits and vegetables contain vitamin C and organic acids (e.g., citric acid) increasing absorption of nonheme iron when consumed in the same meal

Vitamin C degrades with cooking, so consumption of uncooked (or lightly cooked) fruits and vegetables with high vitamin C content

Vitamin A and carotenoids also appear to enhance iron absorption by overcoming the inhibiting effect of polyphenols and phytates (found in whole grains) on iron absorption.

Adding vitamin A to an iron supplement regimen has also been shown to result in greater anemia reduction than iron alone produces

Nutritional Considerations

Tea, coffee, and cocoa should not be consumed with meals if poor iron status is suspected.

Polyphenols and tannins in these beverages inhibit the absorption of nonheme iron.

Black tea appears to be the most potent in this regard

separate tea and coffee drinking from meal times; consumption 1-2 hours later will not inhibit iron absorption


Celiac disease/atrophic gastritis/H. pylori


Anemia in male or menopause female??


blood loss

dietary intake

reduced absorption







IDA

```
• SI (Serum iron)?
```

Ferritin? Protoporphyrin?

·TBC?

TS? Hepcidin?


Ferritin is acute phase protein

Ferritin>200

Ferritin< 15

15< Ferritin<100

Case: ckd Ferritin: 120?????



Laboratory findings during the development of iron deficiency

| | Normal | Iron deficiency without anemia | Iron deficiency with mild anemia | Severe iron deficiency with severe anemia |
|---|---|---|---|---|
| Hemoglobin | Normal range* | Normal range* | 9 to 12 g/dL (90 to 120 g/L) | 6 to 7 g/dL (60 to 70 g/L) |
| Red blood cell size and appearance | Normal | Normal | Normal or slight hypochromia (slight decrease in MCHC) | Microcytosis (decrease in MCV) and hypochromia (decrease in MCHC) |
| Serum ferritin | 40 to 200 ng/mL (40 to 200 mcg/L; 89.9 to 449 picoM/L) | <40 ng/mL ¹ (<40 mcg/L; <89.9 picoM/L) | <20 ng/mL (<20 mcg/L; <45 picoM/L) | <10 ng/mL (<10 mcg/L; <22.5 picoM/L) |
| Serum iron | 60 to 150 mcg/dL (10.7 to 26.7 microM/L) | 60 to 150 mcg/dL (10.7 to 26.7 microM/L) | <60 mcg/dL (<10.7 microM/L) | <40 mcg/dL (<7.1 microM/L |
| Total iron-binding capacity (TIBC; transferrin) | 300 to 360 mcg/dL (53.7 to 64.4 microM/L) | 300 to 390 mcg/dL (53.7 to 69.8 microM/L) | 350 to 400 mcg/dL (62.6 to 71.6 microM/L) | >410 mcg/dL (>73.4 microM/L) |
| Transferrin saturation (serum iron/TIBC) | 20 to 50% | 20% | <15% | <10% |
| Reticulocyte hemoglobin ^[1] | 30.6 to 35.4 pg | 22.3 to 34.7 pg | 14.8 to 34.0 pg | Data not available |
| Bone marrow iron stain | Adequate iron present | Iron absent | Iron absent | Iron absent |
| Erythrocyte zinc protoporphyrin, ng/mL RBC | 30 to 70 | 30 to 70 | >100 | 100 to 200 |

CLINICAL MANIFESTATIONS

- Typical symptoms include
- Fatigue
- Pica (pagophagia, ice craving)
- Restless legs syndrome
- Headache
- Exercise intolerance
- Exertional dyspnea
- Weakness

Findings on examination


The physical examination in individuals with iron deficiency (with or without anemia) may be normal or it may reveal following findings

- Pallor
- Dry or rough skin
- Atrophic glossitis with loss of tongue papillae, what accompanied by tongue pain or dry mouth



Reprinted by permission from: Macmillan Publishers Ltd: British Dental Journal. Scully C, Felix DH. Oral medicine-update for the dental practitioner: red and pigmented lesions. Br Dent J 2005; 199:639. Copyright © 2005.

- Cheilosis (also called angular cheilitis
- Koilonychia (spoon nails)
- Alopecia (rare) in especially severe of



Eryth

Angular cheilitis

Repro Visua



Reproduced with permission from: Stedman's Medical Dictionary.

Copyright © 2008 Lippincott Williams & Wilkins.

UpTo Date

Whom to treat

 all patients with iron deficiency anemia and most patients with iron deficiency without anemia should be treated.

- The cause of iron deficiency also must be identified and addressed, especially in adults with new onset iron deficiency.
- A healthy diet provides sufficient iron for physiologic needs but cannot correct iron deficiency

Oral versus IV iron

 generally treat patients who have uncomplicated iron deficiency anemia with oral iron due to the ease of administration

 We often use IV iron when treating pregnant women and individuals with inflamematory bowel disease, gastric surgery, or chronic kidney disease

Adverse effects of oral iron

- Gastrointestinal side effects are extremely common with oral iron administration.
- Strategies to reduce these effects:
- Increasing the interval to every other day if not done already.
- Making dietary modifications (taking iron with food or milk), although this may reduce absorption
- Switching to a formulation with a lower amount of elemental iron

- Once a tolerated dose is found, the patient can sometimes increase the dose slowly as tolerated
- As noted above, for many populations, another option is switching to IV iron.
- Use of IV iron eliminates all of the gastrointestinal side effects of iron, which are due to direct effects of iron on the intestinal mucosa.
- If the patient switches to IV iron, oral iron should be discontinued

RESPONSE TO IRON SUPPLEMENTATION

- The patient will note an improved feeling of well-being within the first few days of treatment
- restless legs syndrome accompanies documented iron deficiency, the overwhelming majority will experience complete or near complete relief within 72 hours of the infusion, often on the first night thereafteroll.
- The hemoglobin concentration will rise slowly, usually beginning after approximately one to two weeks of treatment, and will rise approximately 2 g/dL over the ensuing three weeks
- The hemoglobin deficit should be halved by approximately one month, and the hemoglobin level should return to normal by six to

Table A. Suggested scheme for daily iron supplementation in infants and young children aged 6–23 months

| TARGET GROUP | Infants and young children (6–23 months of ag | | |
|------------------------|---|--|--|
| SUPPLEMENT COMPOSITION | 10–12.5 mg elemental iron ^a | | |
| SUPPLEMENT FORM | Drops/syrups | | |
| FREQUENCY | Daily | | |
| DURATION | Three consecutive months in a year | | |
| SETTINGS | Where the prevalence of anaemia in infar or higher ^b | | |

liposofier"



ren is 40%

ous fumarate or

^{2 10–12.5} mg of elemental iron equals 50–62.5 mg of ferrous sulfate heptahydrat 83.3–104.2 mg of ferrous gluconate.

In the absence of prevalence data in this group, consider proxies for high risk of anaemia. For the most recent estimates, visit the WHO-hosted Vitamin and Mineral Nutrition Information System (VMNIS) (7).

Table B. Suggested scheme for daily iron supplementation in children aged 24-59 months

| TARGET GROUP | Preschool-age children (24–59 months of age |
|------------------------|---|
| SUPPLEMENT COMPOSITION | 30 mg elemental iron ^a |
| SUPPLEMENT FORM | Drops/syrups/tablets |
| FREQUENCY | Daily |
| DURATION | Three consecutive months in a year |
| SETTINGS | Where the prevalence of anaemia in infants a or higher ^b |



- 2 30 mg of elemental iron equals 150 mg of ferrous sulfate heptahydrate, 90 mg of ferrous fumarate or 250 mg of ferrous gluconate.
- In the absence of prevalence data in this group, consider proxies for high risk of anaemia. For the most recent estimates, visit the WHO-hosted Vitamin and Mineral Nutrition Information System (VMNIS) (7).

Table C. Suggested scheme for daily iron supplementation in school-age children (5–12 years of age)

| TARGET GROUP | School-age children (5–12 years of age) |
|------------------------|---|
| SUPPLEMENT COMPOSITION | 30–60 mg elemental iron ^a |
| SUPPLEMENT FORM | Tablets or capsules |
| FREQUENCY | Daily |
| DURATION | Three consecutive months in a year |
| SETTINGS | Where the prevalence of anaemia in infants and young children is 40% or higher ^b |


^{30–60} mg of elemental iron equals 150–300 mg of ferrous sulfate heptahydrate, 90–180 mg of ferrous fumarate or 250–500 mg of ferrous gluconate.

In the absence of prevalence data in this group, consider proxies for high risk of anaemia. For the most recent estimates, visit the WHO-hosted Vitamin and Mineral Nutrition Information System (VMNIS) (7).

| Age groups | Indications for supplementation | Dosage schedule | Duration |
|--|--|--|---|
| Low-birth-weight infants | Universal supplementation | Iron: 2 mg/kg body weight/day | From 2 months of age up to 23 months of age |
| Children from 6 to 23 months of age | Where the diet does not include foods fortified with iron or where anaemia prevalence is above 40% | Iron: 2 mg/kg body weight/day | From 6 months of age up to 23 months of age |
| Children from 24 to 59 months of age | Where anaemia prevalence is above 40 % | Iron: 2 mg/kg body weight/day up to 30 mg | 3 months |
| School-aged children (above 60 months) | Where anaemia prevalence is above 40 % | Iron: 30 mg/day Folic acid: 250 μg/day | 3 months |
| Women of childbearing age | Where anaemia prevalence is above 40 % | Iron: 60 mg/day Folic acid: 400 μg/day | 3 months |
| Pregnant women | Universal supplementation | Iron: 60 mg/day Folic acid: 400 μg/day | As soon as possible after gestation starts - no later than the 3 rd month - and continuing |
| Lactating women | Where anaemia prevalence | Iron: 60 mg/day | for the rest of pregnancy |
| | is above 40 % | Folic acid: 400 µg/day | 3 months post-partum |

Strategies for Increasing Dietary and Supplemental Iron

| Strategy | Action |
|--|--|
| Increase iron through cooking. | Use cast Iron skillets for acidic food preparation, such as tomato sauce. Iron will leech out of the iron skillet into the food. |
| Increase iron through consumption with a source of vitamin C. | Drink orange juice with food sources of iron, such as spinach. |
| Increase iron through consumption of foods with higher iron bioavailability. | Lean meats contain highly absorbable iron. |
| Increase the use of high-iron foods in the diet. | Find acceptable ways to prepare spinach, use blackstrap molasses or include beans. |
| Increase iron intake through the use of iron-fortified foods. | Read ingredient labels for iron fortification of cereals and other products. |
| Increase iron absorption through proper supplementation. | Take an iron supplement at a different time than other mineral supplements or multivitamin-mineral preparations to avoid competitive absorption. |
| | Take supplements with a vitamin C source and preferably on an empty stomach. |
| | Continue vitamin administration and reduce negative side effects of constipation and cramping through alternative actions. |









DIFFERENTIAL DIAGNOSIS

IDA or Thalassemia


| | IDA | Thalassemia |
|----------|----------|-------------|
| RBC | ↓ | NL |
| MCV | ↓ | |
| RDW | | NL OR |
| Ferritin | ↓ | NL OR 1 |

MI

 $DF=MCV-RBC-(5\times Hb)-3.4$

-: Thalassemia

+: IDA



Thalassemia+ ID???

| Test | | Result | <u>Unit</u> | Expected Value | Neutrophils | 48.1 % 43.3 % |
|--|-------------|--|--|--|---|-------------------------|
| Test CBC WBCs RBCs Hb Hct MCV MCH MCHC Platelets RDW-CV PDW MPV P-LCR Hypochromia Microcytosis = High L = Low CBC results reporte hecked by : Saadat | L L L | 6510 5.75 12.0 39.2 68.2 20.9 30.6 276000 13.3 16.5 11.8 54.7 (++) | - /uL mil/uL g/dL % fL pg g/dL /uL % fL fL % | 4000-11000 4.2-5.4 12-16 37-47 77-97 26-34 32-36 150000-400000 11-14 9.3-18 7.5-11.0 20-36 Hematology Analyzer | Lymphocytes Monocytes Eosinophils Basophils | 6.1 % 2.1 % 0.4 ° |

| Blood Biochemistry | | | | |
|--------------------|--------|-------|-------------|--|
| Test Iron | Result | Unit | Method | Expected Value |
| TIBC | 99 | ug/dL | Ferrozine | 40-140 |
| Ferritin | 271 | ug/dL | Persipitant | Adult female: 250-425 First Trimester: 235-410 Second Trimester: 302-519 Third Trimester: 380-597 |
| remun | 66.7 | ng/ml | ELISA | Premenopause: 8-150 Postmenopause: 25-230 |

Results reported by Hitachi 902 Roche Diagnostics GmbH.

Checked by: Khodaparast

Chromatography

| Tool | | Result | <u>Unit</u> | Method | Expected Value |
|----------------------|---|--------|-------------|--------|----------------|
| <u>Test</u> | | | S.Quant | LPLC | |
| Hb. Electerophoresis | | 0.5 | % | LPLC | Less than 2.0 |
| Hb.F | | 0.5 | % | LPLC | 1.5 - 3.5 |
| Hb.A2 | Н | 4.2 | % | LPLC | 96 - 98.5 |
| Hb.A | L | 95.3 | 70 | | |

IDA Vs ACD

patients with ACD/AI may have microcytic or normocytic anemia with a low serum iron and low transferrin (or TIBC)

The best test: ferritin

| Iron parameter | IDA | ACD |
|----------------|-----|-----|
| Serum iron | 1 | 1 |
| TIBC | † | 1 |
| Serum ferritin | 1 | 1 |
| Serum sTfR | † | N |


Female, 40 years old, RA Which one is correct?

Hb: 11.5

MCV: 85


Mcv: 77

Mcv: 105



| شاخصهای آزمایشگاهی | آئمی فقر آهن | تالاسمى | آنمی سینروپلاست | آنمی بیماری عزمن |
|-------------------------|--------------------|-------------------------------|--------------------|-------------------------------|
| لام محیطی | میکرو/ هیو | مبكرو/ هبيو يا سلول هدف | متغير | طبیعی گاهی میکرو اهابیو |
| SI | 1 | ↑ t N | ↑υN | |
| TIBC | 1 | N | N | 1 |
| T sat (اشیاع ترالسفرین) | 1 | ↑ t N | † t N | 1 |
| Ferritin | 1 | † t N | † 5N | 1 |
| الگوی Hb | N | *Abnormal | N | N |
| رعال باشد. | ممكن است ن | ولى در آلفا تالاسمى | می غیر طبیعی است | * در بنا تالاسد |

Macrocytosis (high MCV)



Macrocytosis (high MCV)

- MCV & RDW MEGALO
- MCV & NL RDW ______ MACRO

 Vitamin B12 and folate deficiencies are often considered together, although folate deficiency has become less common in individuals who are living in developed countries and consuming a normal diet

| Table 1 | Q R Food | Sources | nt \ | /itamin | B |
|----------|-----------|----------|------|----------------|-----|
| I GNIE 1 | 0.0 1 00u | Jour CC2 | VI I | / LCOI I III I | D17 |

| Food | Vitamin B ₁₂ (μg) | | |
|--------------------|------------------------------|--|--|
| Beef liver—1 ounce | 32 | | |
| Clams—1 ounce | 16 | | |
| Oysters—1 ounce | 14 | | |
| Brewer's yeast—2 T | 3.0 | | |
| Lobster—3 ounces | 3.0 | | |
| Pot roast—3 ounces | 3.0 | | |
| Yogurt—1 cup | 1 | | |

Source: Adapted from: the USDA Agricultural Handbook Series. Available at http://www.usda.gov

Table 19.9 Food Sources of Folate

| Folate (μg) | | |
|-------------|--|--|
| 263 | | |
| 262 | | |
| 180 | | |
| 115 | | |
| 90 | | |
| | | |

Source: Adapted from: the USDA Agricultural Handbook Series. Available at http://www.usda.gov

Vitamin B12 deficiency

Decreased intake (eg, reduced intake of animal products, strict vegan diet, breastfeeding by a vitamin B12-deficient mother).

Decreased absorption (eg, gastrectomy, bariatric surgery, Crohn disease, celiac disease, pancreatic insufficiency, bacterial overgrowth, gastric atrophy associated with aging).

Medications and drugs that interfere with absorption or stability (eg, <u>metformin</u>, histamine receptor antagonists, proton pump inhibitors, <u>nitrous oxide</u>)

Other autoimmune conditions, such as thyroid disease or vitiligo, in individuals with pernicious anemia.

Folate deficiency

- Increased requirements due to pregnancy, hemolytic anemia.
- Decreased intake, especially in individuals with excessive alcoholouse and corresponding reductions in dietary intake of folate-rich foods such as fresh vegetables and fortified grains.
- Residence in a place where routine folate supplementation of foods does not occur.
- Decreased absorption in the setting of gastric bypass surgery.
- Loss during hemodialysis (along with other water-soluble vitamins)
- ✓ Medications and drugs that interfere with metabolism (eg, method exate, sullasatame)

Overview of evaluation

- In countries in which dietary deficiency is less of a concern, witaming B12 and/or folate deficiency may be suspected in a patient with one or more of the following
- Unexplained anemia, macrocytosis (mean corpuscular volume [MCV] >100 fL), pancytopenia, or hypersegmented neutrophils
- Unexplained neurologic or psychiatric symptoms.
- Strict vegan diet or conditions that may interfere with absorption.
- Certain autoimmune disorders such as thyroiditis or vitiligo, or those taking chronic therapy.
- Gastrointestinal symptoms such as sore tongue, anorexia, or diarrhea

• For an individual with suspected vitamin 812 or folate deficiency, the history should include questions about previously diagnosed associated conditions, particularly celiac disease or inflammatory bowel disease; bariatric, gastric, or intestinal surgery; reduced dietary intake (eg, vegan or vegetarian diet, lack of fresh vegetables); alcohol use (as an independent cause of macrocytic anemia and as a possible predictor of reduced dietary intake); and any symptoms, including subtle neurologic or psychiatric symptoms, such as those described above

- The MCV does not help distinguish vitamin B12 deficiency from folate deficiency.
- Further, if a patient has concomitant microcytosis due to iron deficiency or thalassemia, the macrocytosis may be masked on a CBC because the MCV reflects the average volume of all RBCs.
- However, in this instance (combined macrocytosis and microcytosis), the red cell distribution width (RDW) may be increased

Serum vitamin B12 and folate levels

- For individuals with typical findings on the CBC and a low reticulocyte count, the only initial testing needed is a serum vitamin B12 and folate level
- We often omit the folate level if the individual is consuming a normal diet containing folate-supplemented grains and has normal gastrointestinal anatomy and function, as folate deficiency in these individuals is rare
- We test both vitamin B12 and folate levels in individuals with gastrointestinal conditions, excess alcohol use, or dietary patterns known to cause both deficiencies

 Periodic monitoring of graphs is a levels may be appropriate in individuals with intestinal disorders that might affect absorption of vitamin B12, including celiac disease, inflammatory bowel disease, small intestinal bacterial overgrowth, ileal resection, radiation enteritis, and chronic matter therapy

- Typical values for vitamin B12 are as follows:
 - Deficient: <200 pg/mL
 - Borderline: 200 to 300 pg/mL
 - Normal: >300 pg/mL
- Typical values for folate are as follows:
 - Deficient: <2 ng/mL
 - Borderline: 2 to 4 ng/mL
 - Normal: >4 ng/mL

Additional testing for selected individuals


- Metabolite testing (MMA and homocysteine)
- The normal ranges for MMA and homocysteine are laboratorydependent; laboratory-specific and assay-specific cutoffs should be used. Examples of typical normal ranges are: MMA 70 to 270 nmol/L; homocysteine 5 to 15 micromol/L. Interpretation is as follows:

MMA and homocysteine normal – No deficiency of _____ or folate

MMA and homocysteine elevated – Deficiency of (does not eliminate the possibility of folate deficiency).

MMA normal, homocysteine elevated – No deficiency of **MMA**. Consistent with deficiency of folate.

Diagnostic testing for suspected vitamin B12 or folate deficiency





Treatment of vitamin B12 deficiency

Parenteral The typical dose for children is 50 to 100 mcg parenterally once per week until the deficiency is corrected and then once per month (cyanocobalamin) or once every other month (cyanocobalamin) or children are not well established.

 The typical dose for adults is 1000 mcg parenterally once per week until the deficiency is corrected and then once per month (cyanocobalamin) or once every other month (hydroxocobalamin).

- Oral In adults with normal absorption, oral dosing is equally effective at a dose of 1000 mcg orally once per day.
- For individuals with impaired absorption of vitamin B12, therapy with very high oral doses of oral vitamin B12 (eg, 1000 to 2000 mcg daily) will be effective as long as the dose is high enough to provide absorption via a mechanism that does not require intrinsic factor or a functioning terminal ileum (ie, passive diffusion/mass action)







Treatment of folate deficiency

- Folate deficiency is typically treated with oral folic acid (1 to 5mg daily)
- This dose is usually sufficient even if malabsorption is present, because it is considerably in excess of the 200 mcg (0.2 mg) recommended dietary allowance mg daily)
- For those with a reversible cause of deficiency, therapy is generally given for one to four months or until there is laboratory evidence of hematologic recovery







 Intravenous folic acid may be appropriate in certain settings, such as individuals who are unable to take an oral medication (eg, due to vomiting or those who have severe or symptomatic anemia due to folate deficiency and hence have a more urgent need for rapid correction It is important to be aware that administration of <u>folic acid</u> can partially reverse some of the hematologic abnormalities associated with <u>vitamin</u>

<u>B12</u> deficiency; however, the <u>neurologic manifestations</u> of vitamin B12 deficiency are not treated by folic acid.


Thus, administration of folic acid to an individual with vitamin B12 deficiency can potentially mask untreated vitamin B12 deficiency or even worsen the neurologic complications

- Laboratory markers improve in the following time scales
- Hemolysis markers Day 1 to 2
- Reticulocytosis Day 3 to 4
- Anemia Week 1 to 2 (initial improvement) and week 4 to 8 (normalization)
- Hypersegmented neutrophils Day 10 to 14
- Leukopenia and/or thrombocytopenia Week 2 to 4

Folia and, folinic acid, and 5-MTHF are all effective in treating foliate deficiency

Folinic acid is typically used to prevent toxicities
 of the local and to potentiate cytotoxicity of the local (FU) in
 chemotherapy regimens for colon cancer.

Macrocytosis Evaluation of Macrocytic Anemia



 An MCV value >115 fL is more specific to warm 5/2 or folate deficiency than other conditions in the differential diagnosis such as hypothyroidism or myelodysplastic syndrome.

Normocytic (normal MCV)

- A normal MCV (80 to 100 fL) is the most common finding in anemic men and postmenopausal women.
- Normocytic anemias can be more challenging to evaluate than anemias with an MCV that is obviously low or high. Causes are more numerous and may be multifactorial, an underlying condition may not be apparent, and other findings may be nonspecific

- Often normocytic anemia is associated with a slightly elevated RDW, and the reticulocyte count is not substantially increased (and may be decreased).
- An increased RDW may indicate a population of microcytic or macrocytic RBCs that is too small to shift the MCV out of the normal range, or combined microcytic and macrocytic processes, such as iron deficiency plus vitamin B12 or folate deficiency

Causes

- Nutrient deficiency
- Multiple causes: deficiency of vitamin B12 and iron in an individual with celiac disease or autoimmune gastritis
- ACD/AI
- CKD
- HF
- Early blood loss: Blood loss that has not yet caused iron deficiency

- Male, RBC: 5.8
- WBC: 11.5
- PLT: 500
- HB: 18
- HCT: 55%
- Diagnosis & treatment?

case2

- Female,
- · Hb: 17
- Hct: 47%
- MCV: 85
- MCH: 28
- Wbc: 7<u>.1</u>
- Plt: 150

- Male
- RBC: 5.7
- Hb: 12
- Mcv: 68.2
- MCH: 20.9


Male with neurophathy

• DH: omeprazole


• Hb: 14

• MCV: 110

- Female
- · HB: 13
- HCT: 40%
- Ferritin: 14
- TIBC: 390



Initial evaluation of low hemoglobin, hematocrit in adults*



This algorithm is intended for use with additional UpToDate content on anemia.

CBC: complete blood count; PT: prothrombin time; aPTT: activated partial thromboplastin time; BUN: blood urea nitrogen; RBC: red blood cell; MCV: mean corpuscular volume; TIBC: total iron binding capacity; ESR: erythrocyte sedimentation rate; LDH: lactate dehydrogenase; TSH: thyroid-stimulating hormone.

- * Reference values for RBC parameters depend on age, sex, and other factors. Interpretation of a specific abnormal test result should be based upon the reference range reported by the laboratory.
- ¶ Life-saving interventions should not be delayed while awaiting the results of diagnostic testing.
- Δ Liver biochemical tests include total and indirect bilirubin, alanine aminotransferase, and aspartate aminotransferase.
- Review of the peripheral blood smear by an experienced individual may identify abnormalities not detected by automated machines but is not required in all patients.
- § Common sources are menstrual and occult gastrointestinal bleeding.



